Enzon Pharmaceuticals, Inc. (ENZN)

Other OTC - Other OTC Delayed Price. Currency in USD

0.1050

-0.0000

(-0.02%)

At close: 11:07AM EST

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	0.1050
Open	0.1050
Bid	0.3800 x 3000
Ask	1.4100 x 200
Day's Range	0.1050 - 0.1050
52 Week Range	0.0900 - 0.2800
Volume	16,334
Avg. Volume	14,922

Market Cap	7.791M
Beta (5Y Monthly)	0.42
PE Ratio (TTM)	∞
EPS (TTM)	0.0000
Earnings Date	Feb 05, 2024 - Feb 10, 2024
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	Sep 30, 2019
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ENZN

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

ENZON PHARMACEUTICALS INC
NBIX: Raising target price to $118.00NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $118.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
Rating
Fair Value
Economic Moat
3 days agoArgus Research